Updated: Oct 20
Medically reviewed by ChinaCureLink Team
Table of Content
Why This Case Matters
This case follows Mr. Rajan (alias), a 73-year-old patient from Canada with type 2 diabetes that had stopped responding adequately to standard treatment, who traveled to a hospital inside Hainan's Boao Lecheng Pilot Zone in China to access a specialized stem cell therapy not available through conventional care in Canada.
For patients facing declining diabetes control despite standard medication, ChinaCureLink offers a direct path to explore the same kind of advanced treatment Mr. Rajan accessed — helping evaluate whether a comparable pathway could be relevant to your own case, and coordinating the process from case review through treatment and follow-up.
Key Takeaways |
|
Patient Background
Mr. Rajan had lived with type 2 diabetes for many years, managing it in Canada with oral hypoglycemic medications and insulin injections. Despite ongoing treatment, his blood sugar control kept slipping, and he developed significant insulin resistance alongside early complications, including limb numbness that wasn't improving. After extensive research into more advanced options, he decided to pursue stem cell treatment in China rather than continue standard management alone.
The Care Team and Approach
Mr. Rajan traveled to a hospital operating within Hainan's Boao Lecheng International Medical Tourism Pilot Zone, a special regulatory zone built specifically to accelerate clinical access to cutting-edge biomedical technologies not yet approved elsewhere in China. His treatment was personally led by Professor Liang Wei (pseudonym), Technical Director and Principal Investigator of the hospital's dedicated mesenchymal stem cell program for type 2 diabetes.
The treatment used human umbilical cord-derived mesenchymal stem cells, delivered as an individualized protocol built around a precise evaluation of his specific disease profile — a fundamentally different approach from oral medication or insulin, which manage blood sugar without addressing the underlying insulin resistance and declining islet function driving the disease. What made this treatment accessible to Mr. Rajan in the first place was the pilot zone's regulatory pathway itself, which allows approved facilities to bring select advanced therapies into real clinical use years ahead of standard nationwide approval elsewhere in China.
Treatment Timeline/ Process
In Canada
Diagnosed with type 2 diabetes and managed long-term with oral hypoglycemic medications and insulin injections
Blood sugar control continued to decline, with significant insulin resistance and early complications, including limb numbness, that weren't improving
In China
Traveled to a hospital within Hainan's Boao Lecheng International Medical Tourism Pilot Zone
Became the first international diabetic patient to receive the hospital's individualized human umbilical cord-derived mesenchymal stem cell treatment
Began a structured one-year follow-up disease management program to support his care over the longer term
Outcome
At the time of reporting, Mr. Rajan had just completed the procedure, and his one-year follow-up program was only just beginning. Broader trial data on this treatment class gives a general sense of its potential (one Chinese Phase II trial found around 60% of patients reduced their medication dosage at 12-month follow-up, with 15–20% achieving insulin independence).
How ChinaCureLink Can Help International Patients to Access This Treatment
Patients whose diabetes has stopped responding adequately to standard medication often reach a point where conventional treatment pathways at home have little left to offer. ChinaCureLink helps these patients get a specialized case review and connects them with hospitals in China's special medical zones offering access to advanced regenerative treatments not yet available elsewhere — coordinating medical record translation, case evaluation, and every logistical step of care from first inquiry through treatment and follow-up.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialists to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
How can I access stem cell treatment for type 2 diabetes in China as an international patient?
Access typically starts with a case review, where medical records and treatment history are submitted for evaluation by the treating facility. ChinaCureLink coordinates this process and helps determine whether this type of treatment may be a fit for your case.
Is this stem cell treatment only available in this specific zone in China?
Yes — this treatment is accessible through a special regulatory pathway unique to Hainan's Boao Lecheng Pilot Zone, which allows approved facilities to offer certain advanced therapies ahead of standard nationwide approval elsewhere in China.
What should I expect during a stem cell treatment trip to China for diabetes?
The process generally includes an initial case evaluation, an individualized treatment protocol, and a structured follow-up program afterward. ChinaCureLink can walk you through what to expect at each stage based on your specific case.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
